ArticleJournal of personalized medicine2022

1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients.

Filippo Alongi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.